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9I INTRODUCTION
I  INTRODUCTION
Breast cancer is the most common cancer of women in west-
ern countries, and its incidence is increasing (Garfinkel et al.
1994; Broeders and Verbeek 1997). Overall, 10-15% of all
women will develop breast cancer during their lifetime
(Broeders and Verbeek 1997; López-Otín and Diamandis
1998).  In Finland, each year are diagnosed approximately
3300 new cases of breast cancer (Finnish Cancer Registry
1997). Yet, in spite of the increasing incidence, the mortality
for breast cancer has not increased during the last years.
This apparent discrepancy can perhaps be explained by the
earlier diagnosis (Garfinkel et al. 1994; Garne et al. 1997; UK
Trial of Early Detection of Breast Cancer Group 2000), by
the appearance of less malignant forms of the disease (SEER
Cancer Statistics 1997), and also by the progress in treatment
(Early Breast Cancer Trialists´ Collaborative Group 1992;
2000).
The ethiopathogenesis of breast cancer is still unknown,
but estrogen plays a major role (Mettlin 1992; Broeders and
Verbeek 1997; López-Otín and Diamandis 1998). This is sup-
ported for example by the fact that breast cancer occurs
almost exclusively in women. Observational epidemiologi-
cal studies also show increased risk of breast cancer after
the long-term use of estrogen (ERT) or estrogen plus pro-
gestin (HRT) replacement therapy (Collaborative Group on
Hormonal Factors in Breast Cancer 1997). Therefore ERT/
HRT has not been recommended for postmenopausal wom-
en with a history of breast cancer (Marchant 1994; Colditz
1997; Consensus Statement 1998).
Antiestrogens are an interesting group of drugs owing both
antiestrogenic and estrogenic activity (Buckley and Goa 1989;
Wiseman and Goa 1997). They are used in the treatment
(Early Breast Cancer Trialists´ Collaborative Group 1998;
Pyrhönen et al. 1999) and also in the prevention of breast
cancer (Fisher et al. 1998). At present two antiestrogens,
tamoxifen and toremifene, which are structurally related
compete for favor in clinical routine (Pyrhönen et al.1999).
These drugs have a number of beneficial estrogenic effects
(Neven et al. 1993) but on the other hand, antiestrogens do
not alleviate vasomotor symptoms but may even aggravate
them (Love et al. 1991).
The present study was designed firstly to explore the use-
fulness and safety of ERT/HRT in women with a history of
breast cancer and secondly, to compare the effects of
tamoxifen and toremifene on female reproductive organs,
vascular endothelium, and bone.
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II REVIEW OF THE LITERATURE
1 BREAST CANCER
1.1 Incidence
It has repeatedly been established that the incidence of breast
cancer has increased approximately by 1% per year in Fin-
land (Finnish Cancer Registry 1997). Breast cancer is most
common in North America and in Western Europe and most
infrequent in Asia, e.g. in Japan (Figure 1). In Finland, the
incidence of breast cancer has almost doubled since the 1970s
(Figure 2) (Finnish Cancer Registry 1997, Statistics Centrum
of Finland). Breast cancer accounts for approximately 30%
of all malignant tumors in Finnish women.  Due to the mam-
mographic screening programs, the detection of early breast
cancer has increased most drastically. This was seen, for
example, in the United States where the proportions of stage
I and of in situ cancer have increased markedly, whereas the
Figure 1.
The age adjusted incidences of breast cancer in
1990 at ages 0-74 years in different countries
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Figure 2.
The incidence of breast cancer (grey bars) and deaths (white
bars) for breast cancer in Finland (Finnish Cancer Registry,
Statistics Centrum of Finland)
Figure 3.
Percentual change in incidence of in situ and St I-IV
breast cancer from 1983 to 1995 in the United States
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proportions of stage II-IV breast cancer have decreased (Fig-
ure 3) (SEER Cancer Statistics 1997). A similar phenomenon
has also taken place in Finland (Klemi et al.1992). This could
explain, at least partly, why the increased incidence of this
cancer has not led to an increase in mortality, but in con-
trast, the mortality rate due to breast cancer may even be
decreasing, at least in Finland (Figure 2) and also in Europe
(Peto et al. 2000).
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1.2 Risk factors
Although the pathogenesis of breast cancer is not under-
stood, several inherent and/or clinical factors can indicate
an increased risk (Table 1) (Mettlin 1992; Collaborative Group
on Hormonal Factors in Breast Cancer 1996, 1997; Broeders
and Verbeek 1997; López-Otín and Diamandis 1998, Colditz
and Rosner 2000). One of the well established risk factors is
age because the incidence of breast cancer, as that of almost
any cancer, increases with advancing age. Family history of
breast cancer denotes a clearly increased risk, and genetic
predisposition is detectable in approximately 5-10% of all
cases with breast cancer (Broeders and Verbeek 1997). Two
major gene mutations related to breast cancer have been
identified. BRCA1 gene is located on the long arm of chro-
mosome 17 and BRCA2 on the long arm of chromosome 13
(López-Otín and Diamandis 1998). Furthermore, the locus
of the third candidate BRCA gene has been identified also
on the long arm of chromosome 13 (Kainu et al. 2000).
Estrogen-related risk factors are for example female gen-
der, young age at menarche, high age at menopause, and
postmenopausal obesity (Kelsey et al. 1993; Broeders and
Verbeek 1997; López-Otín and Diamandis 1998). The effect
of parity has been also widely studied. Women with a first
pregnancy after 35 years of age or nulliparous women have
a higher risk for breast cancer, whereas an age below 21
years at the first full-term pregnancy seems to protect against
breast cancer (Kelsey et al. 1993; Pathak et al. 2000). Also
long-term postmenopausal use of ERT/HRT has been linked
to the increased risk of breast cancer (Collaborative Group
on Hormonal Factors in Breast Cancer 1997; Colditz and
Rosner 2000). However, it is noteworthy that a quarter of
breast cancer patients have none of these risk factors and all
risk factors combined could account for less than 30% of the
breast cancer incidence (Mettlin 1992).
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Table 1.
Major risk factors for breast cancer
Factor Increased/decreased risk
Female gender 100 fold compared to males
Age Doubles every 10 years until
menopause
Socioeconomic group Highest incidence in high
economical standard (I and II)
Diet High intake of unsaturated fat
increases  the risk
High intake of soyproducts
decreases the risk
Obesity Postmenopausal obesity
(BMI >35 kg/m2) doubles the risk
Alcohol consumption Daily use of alcohol increases
the risk
Family history of breast cancer A first degree relative with breast
cancer before the age of 50
doubles the risk
Cancer in one breast 3 to 5-fold cancer risk in
contralateral breast
Previous atypical hyperplasia 4 to 5-fold risk
Endometrial and ovarian cancer 1.5 to 2-fold risk
Age at menarche Age below 12 years increases
the risk
Age at menopause Late age increases the risk
Nulliparity Increases the risk
Age at first full term pregnancy High age at first delivery
increases the risk
Lactation Lactation over 24 months
decreases the risk
Oral contraceptives (OCC) Current use of OCCs increases
the risk, the risk disappears 10
years after cessation of OCCs
Menopausal hormone use Over 5 years of use increases the
risk, excess risk disappears 5
years after cessation of estrogen
Adding progestin to estrogen still
increases the risk
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1.3 Treatment
Surgery is the cornerstone in the treatment of breast cancer.
It can be conservative (=local excision or segmental resec-
tion) or radical (=mastectomy). The type of operation de-
pends on the size and location of the tumor and also on the
patient´s opinion. Small (diameter below 4 cm), not central-
ly located tumors are almost always suitable for breast sav-
ing surgery, whereas multifocal and central lesions, as well
as large tumors usually require mastectomy. Dissection of
axillary lymph nodes is commonly combined to surgery,
because the nodal status is the most powerful prognostic
factor and guides the use of adjuvant therapy (Carter et al.
1989; Hortobagyi 1998). Because the dissection of axillary
lymph nodes is related to a number of postoperative seque-
lae (lymphoedema, limited movements of shoulder, pain),
recently has been introduced the removal of the sentinel
node to avoid the risk of later complications. The sentinel
node is most likely to drain the primary tumor, and the sta-
tus of the sentinel node accurately predicts the nodal status
of the whole axilla (Krag et al. 1998).
Postoperative radiotherapy is given to reduce the risk of
local recurrences which may occur after conservative sur-
gery (Hortobagyi 1998; Early Breast Cancer Trialists´ Collab-
orative group 2000). After mastectomy, radiotherapy is giv-
en only to patients with T3 tumor (diameter >5 cm) or to
patients with positive axillary nodes because they still have
a risk of local recurrence (Early Breast Cancer Trialists´ Col-
laborative Group 2000).
Postoperative adjuvant chemotherapy and/or hormonal
therapy is given if the cancer has spread to axillary nodes or
if patients have other clinically relevant risk factors for can-
cer recurrence (Early Breast Cancer Trialists´ Collaborative
Group 1992; 1998). Adjuvant chemotherapy is given at three
weeks interval by using a combination of cyclophosphamide
and doxorubicin (CA) or a combination of cyclophospha-
mide, fluorouracil, and methotrexate or epirubicin (CMF or
CEF). CMF regimen improved the 10-year survival by 7% in
node-negative and by 11% in node-positive patients (Early
Breast Cancer Trialists´ Collaborative Group 1992). Also the
rate of local recurrences decreased by 35% (Early Breast
Cancer Trialists´ Collaborative Group 1992).
Postoperative antiestrogen treatment, which has been avail-
able from the seventies (Buckley and Goa 1989), is primarily
given to postmenopausal women with estrogen and/or pro-
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gesterone receptor positive tumors (Early Breast Cancer Tri-
alists´ Collaborative Group 1992; 1998).  Tamoxifen (20-40
mg/day) was the first drug to enter clinical use, and it re-
duced the risk of recurrence by 21% after 1 year of use, by
29% after 2 years of use, and by 47% after 5 years of use
(Early Breast Cancer Trialists´ Collaborative Group 1998).
Correspondingly, mortality decreased by 12%, 17%, and 26%,
respectively (Early Breast Cancer Trialists´ Collaborative
Group 1998). Tamoxifen treatment also prevented the de-
velopment of cancer in the contralateral breast by 47% after
5 years of use (Early Breast Cancer Trialists´ Collaborative
Group 1998).
Toremifene, developed in the 1980´s, is an antiestrogen
which has been clinically used since 1989. Until now it has
been used primarily in the treatment of advanced breast can-
cer (Wiseman and Goa 1997). Toremifene at the dose of 40-
60 mg has an antitumor activity comparable to that of
tamoxifen at the dose of 20 mg (Homesley et al. 1993;
Pyrhönen et al. 1999). The trial on toremifene as an adjuvant
treatment of breast cancer is still continuing (Holli 1998),
and according to the preliminary results tamoxifen and
toremifene appear to have equal clinical efficacy (Holli et al.
2000).
1.4 Prognosis and prognostic factors
Prognosis of breast cancer depends on many different fac-
tors (Table 2) (Joensuu and Toikkanen 1992). The size of
tumor and its possible spread to axillary lymph nodes are
the major prognostic factors (Miller et al. 1994; Abner et al.
1998; Page et al. 1998; Tabár et al. 1999). Patients in whom
cancer has spread beyond the axillary nodes have a much
worse survival rate than patients whose tumor is limited to
the breast (Carter et al. 1989; Page et al 1998). Biological
factors, such as the estrogen and progesterone receptor sta-
tus, histological grading, and proliferation markers, predicts
the behavior of the tumor and helps in choosing suitable
treatments for individual patients (Alanko et al. 1984; Blanco
et al. 1984; Elston and Ellis 1991; Miller et al. 1994; Page et
al. 1998). Histological grading on the scale from I to III is
based on glandular formation, nuclear pleomorphism, and
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frequency of mitoses (Elston and Ellis 1991). Markers of tu-
mor cell proliferation reflect growth potential, and, for in-
stance, the number of cells in S-phase fraction detected by
flow cytometry, the DNA content, the presence of Ki-67 an-
tigen are most often used in clinics (Kallioniemi et al 1987;
Miller et al. 1994; Page et al 1998). The overexpression of
cellular oncogens, such as c-erbB2, c-myc and ras has been
associated with poor prognosis (Miller et al. 1994; Robertson
and Evans 1997). Furthermore, high serum levels of the type
I procollagen propeptides PINP and PICP and low PICP:PINP
ratio have been shown to associate with a higly aggressive
nature of breast cancer (Jukkola et al. 1997). The patient´s
age at diagnosis is also a prognostic marker; younger wom-
en have a poorer prognosis than older patients with an equiv-
alent stage of cancer (Tabár et al. 1999). It is noteworthy that
an earlier detection of cancer, for example by screening mam-
mogram programs, has improved the prognosis of breast
cancer during the last few decades (Garfinkel et al. 1994;
Garne et al. 1997; Tabár et al. 1999, UK Trial of Early Detec-
tion of Breast Cancer group 1999). However, breast cancer
affects the rest of the patient´s life because it may relapse
even 10-20 years after primary diagnosis (Joensuu et al. 1999).
Table 2.
Impact of different prognostic factors on the 5-year survival of
breast cancer patients (Joensuu and Toikkanen 1992)
Prognostic factor 5-year survival (%)
Tumor size <2 cm (T1) 92
2–5 cm (T2) 75
>5 cm (T3) or T4 58
Histologic differentiation Gradus I 97
Gradus II 79
Gradus III 59
Axillary nodes negative 93
positive 62
Estrogen receptors positive 88
negative 65
Progesterone receptors positive 90
negative 69
S-phase fraction <4% 93
>4% 70
DNA – ploidy diploid 89
non-diploid 75
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2 ESTROGEN REPLACEMENT
THERAPY IN POSTMENOPAUSAL
WOMEN
2.1 Postmenopausal health and estrogen
The menopause is accompanied by a number of hormonal
changes reflected in typical climacteric symptoms (Table 3)
(Brincat and Studd 1988; Goldani von Mühlen et al. 1995;
Porter et al. 1996; Dennerstein et al. 2000).  At least 80% of
women suffer from one or more menopausal symptoms
during the first years after menopause. Furthermore, the signs
of urogenital atrophy caused by estrogen deficiency increase
with advanced age, and the risk of urinary tract infections
increases.
Table 3.
The presentation (%) of the most important climacteric symptoms
Symptom Brincat and Goldani Porter et Dennerstein
Studd 1988 von Mühlen al. 1996 et al. 2000
et al. 1995
Hot flushes, sweating 68 74 55-57 41-52
Insomnia / sleeping disorders 51 28 66 38-45
Headache 71 60 32-42
Palpitation 44 37 6-11
Muscle / joint pain 48 67 45-57
Anxiety / irritability 92 25 58-72 26-31
Depression 78 20 51 26-32
Tiredness / lack of initiative 88 32 38-42
Difficulty in concentrating 64 64 20-28
Vaginal dryness 34 25-47
Decreased libido 20 24
Urogenital symptoms 20 48 14-26
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Postmenopausal hypoestrogenism affects also the cardio-
vascular system. The risk of cardiovascular diseases increas-
es after menopause, and women tend to reach the incidence
in that of men (Sullivan and Fowlkes 1996). Indeed, a half of
the women in the western world will get coronary artery
disease and one-third will die from it (Grady et al. 1992).
Therefore, it is understandable that the prevention of cardi-
ovascular disease has been, and still is, one of the priorities
in public health programs.
The peak bone mass, which is reached normally at 25-30
years of age, is 30-50% lower in women  than in men (Chris-
tiansen 1995). Neverthless, bone is affected by estrogen. This
is supported by the finding that estrogen receptors are present
in osteoblasts and osteoclasts, the cells responsible for bone
formation and bone resorption, respectively (Oursler et al.
1993). In menopause, estrogen deficiency leads to increased
osteoclast formation and activity, and thereby it enhances
bone resorption both in trabecular and cortical bone (Rood-
man 1996). This may lead to osteoporosis if a woman lives
long enough (Marcus 1996). The World Health Organisation
has defined osteoporosis as a bone mineral density (BMD),
measured by dual-energy x-ray absorptiometry, which is 2.5
standard deviation (SD) or more below the mean peak value
in young adults. Immediately after menopause, bone mass
decreases by 1-5% per year, and even after the age of 65, the
decrease is 0.5-1% per year (Riis 1996). It has been estimat-
ed that 21% of postmenopausal women in the western coun-
tries will eventually develop osteoporosis (Looker et al. 1995).
Postmenopausal women have a 15% lifetime probability of
suffering a hip fracture and a 1.5% probability of dying from
it (Grady et al. 1992). Also the risk of vertebral fractures
increases, and although these fractures are not associated
with increased mortality, they may cause significant morbid-
ity (Lindsay et al. 1980; Grady et al. 1992). Thus, the preven-
tion of osteoporosis is one of the major challenges in the
health care system in western countries.
2.2 Benefits of estrogen replacement therapy
2.2.1 Quality of life
Menopausal symptoms, such as hot flushes, insomnia, de-
pressive mood and tiredness, are the most common causes
for the initiation of ERT/HRT in clinical routine. Estrogen
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Figure 4.
Improvement of menopausal symptoms as assessed by women´s
health questionnaire (WHQ) before and after 3 months of estro-
gen therapy (n=110, p<0.0001 in all changes) (Wiklund et al.
1992) (grey bars=before therapy, white bars=after therapy)
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replacement therapy eliminates, or at least alleviates rather
effectively these symptoms (Wiklund et al. 1992) and im-
proves the quality of life, as measured by different standard-
ized well-being and health questionnaires (Wiklund et al.
1993; Daly et al 1993) (Figure 4). The benefit in alleviation
of menopausal symptoms has increased the popularity of
ERT/HRT use in the western world, and for instance in Fin-
land 44% of 55-year old women and 5% of 75-year old wom-
en used ERT/HRT in 1997 (Finnish Statistics on Medicines
1997). It is conspicuous that women with higher education
are more likely to start the use of ERT/HRT, and for instance
in Sweden 88% of postmenopausal female gynecologists use
ERT/HRT, whereas the overall frequency of the use of ERT/
HRT among 55-56 years old women was 35% (Andersson et
al. 1998).
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Table 4.
The effect of estrogen replacement therapy on primary (prim) or secondary
(sec) prevention of cardiovascular morbidity and/or mortality in observational
studies
Author No of study Study Event Risk ratio
population design
Bush et al. 1987 2270 sec Cardiovascular death 0.37
Petitti et al. 1987 6093 prim&sec Cardiovascular death 0.60
Henderson et al. 1988 8841 prim&sec Cardiovascular death 0.59
Myocardial infarction 0.54
Sullivan et al. 1990 2268 sec Cardiovascular death 0.16
Hunt et al. 1990 4544 prim&sec Cardiovascular death 0.37
Henderson et al. 1991 8853 prim&sec Cardiovascular death 0.69
Stampfer et al 1991 48470 prim Cardiovascular event 0.56
Wolf et al. 1991 1944 prim&sec Cardiovascular death 0.66
Falkeborn et al. 1992 23174 prim&sec Myocardial infarction 0.81
Grodstein et al. 1996 59337 prim Cardiovascular event 0.39 (HRT)
0.60 (ERT)
Sullivan et al. 1997 1098 sec Cardiovascular death 0.80
O´Keefe et al. 1997 337 sec Cardiovascular event 0.38
Newton et al. 1997 726 sec Myocardial infarction 0.64 (current)
0.90 (past)
Sourander et al. 1998 7944 prim&sec Cardiovascular disease 1.1
Cardiovascular death 0.21 (current)
0.75 (past)
2.2.2 Cardiovascular diseases
Several observational studies show a lower risk of cardio-
vascular diseases and deaths in women taking estrogen alone
or in combination with progestin as compared to non-users
(Table 4). In a recent meta-analysis, the relative risk of cardi-
ovascular diseases among women who had used ERT/HRT
compared to those who had never used ERT/HRT was 0.70
(Barret-Connor and Grady 1998). The largest single study,
Nurses´ Health Study, in which 59 337 women were fol-
lowed up to 16 years, showed that the relative risk of major
coronary disease was 0.60 in current users of ERT and 0.39
in current users of HRT, and 0.85 in former hormone users
(Grodstein et al. 1996). In this study, ERT/HRT did not pre-
vent the risk of a brain ischemic stroke (Grodstein et al.
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1996). However, all these observational studies have been
criticized because healthier women may have been more
prone to start ERT/HRT (“selection bias”): the ERT users have
had fewer cardiovascular risk factors, such as hypertension,
hypercholesterolemia, or obesity before the start of ERT/
HRT (Matthews et al.1996; Rödström et al. 1999).
The clinical data on the cardiovascular benefits of ERT/
HRT in women with ischemic heart disease (“secondary pre-
vention”) are controversial. Previous observational studies
have shown decreased risk of recurrent cardiovascular events
in estrogen users (Bush et al 1987; Sullivan et al. 1990; Hend-
erson et al. 1991; Sullivan et al. 1997; O´Keefe et al. 1997;
Newton et al. 1997) but the only randomized, placebo-con-
trolled trial (HERS study) failed to show any benefit at least
in older (an average of 67 years) women (Hulley et al. 1998).
In this study, placebo or 0.625 mg of conjugated equine
estrogen in combination with 2.5 mg of medroxyprogester-
one acetate were given continuously to 2763 women for an
average of 4.1 years (Hulley et al. 1998). During the first
year of use, the risk of cardiac recurrence was increased (RR
1.52) in hormone users, whereas in 3-5 years, a clear trend
(RR 0.87-0.67) for the favor of HRT was seen (Hulley et al.
1998). In another study, the effect of ERT/HRT on the pro-
gression of coronary atherosclerosis was studied in a rand-
omized, placebo-controlled setting (ERA trial) (Herrington
et al. 2000). In 309 women with angiographically verified
coronary disease, conjugated estrogen with or without pro-
gestin, did not prevent the progression of coronary occlu-
sion during a mean of 3.2 years follow-up, even if ERT/HRT
had favorable effects on LDL and HDL cholesterol levels
(Herrington et al. 2000).
In future, the benefit of estrogen in the primary preven-
tion of cardiovascular diseases should be ascertained by ran-
domized, placebo-controlled studies, and some studies are
presently conducted (The Women´s  Health Initiative Study
Group 1998). Before these results are available there is no
definite truth about the role of ERT/HRT in the primary pre-
vention of coronary heart disease. Yet, it can be questioned
whether truly randomized and placebo-controlled trials in
menopausal research are possible (Ylikorkala 2000).
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2.2.2.1 Mechanisms of vascular protection by
estrogens
Estrogen has several favorable vascular effects, which may
explain its cardiovascular protective efficacy (Table 5). It has
been estimated that the favorable effect of estrogen on plas-
ma lipids can explain approximately 20-30% of cardiovascu-
lar benefits of ERT/HRT (Wild 1996; Tikkanen 1999). Be-
sides high lipid levels, also high plasma homocysteine levels
may indicate a risk of atherosclerosis (Welch and Loscalzo
1998). In a Dutch study, estrogen has been shown to de-
crease these levels especially when the baseline levels were
high (Mijatovic et al. 1998), whereas this was not seen in
Finnish women with normal baseline homocysteine levels
(Eviö et al. 2000). Estrogen has also a favorable effect on
glucose metabolism by enhancing tissue insulin sensitivity
(Barrett-Connor and Laakso 1990; Lindheim et al. 1994; Rau-
daskoski et al. 1999). It is likely that these biochemical find-
ings may require a more prolonged use of ERT before they
become clinically apparent.
Estrogen has also the direct and immediate effects on the
vascular wall. This was first supported by the data which
showed that estrogen binds to the estrogen receptors of vas-
cular endothelial and smooth muscle cells (Mendelsohn and
Karas 1999). Endothelial cells produce a number of agents
with vasodilatory or vasoconstricive activity. One of the best
studied agents is vasodilatory prostacyclin, which is an im-
portant mediator in several occlusive and hypertensive dis-
orders (Ylikorkala et al. 1986; Cinotti and Pugliese 1989; Vane
et al. 1990). It is stimulated by estrogen, at least in cultured
endothelial cells (Mikkola et al. 1995). Endothelial cells also
secrete free radical gas, nitric oxide (NO), which causes va-
sodilatation and inhibits platelet aggregation (Moncada et al.
1991). Nitric oxide production is diminished in conditions
characterized by endothelial damage, such as atherosclero-
sis, hypertension, or diabetes (Moncada et al. 1991). Endothe-
lin-1 (ET-1) is a peptide hormone which is also produced by
endothelial and smooth muscle cells (Masaki 1993). Endothe-
lin-1 is the most potent vasoconstrictor yet discovered (Ma-
saki 1993), and indeed, elevated plasma ET-1 levels have
been detected in several vasoconstrictive diseases, such as
in myocardial infarction, pulmonary hypertension, and athero-
sclerosis (Masaki 1993). Estrogen administration in postmen-
opausal women increases the circulating levels of NO (Cicinel-
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Table 5.
Some plausible biological explanations for the beneficial effect of
estrogen on vascular health
Risk Factor Effect
Lipids and lipoproteins
   Total cholesterol
   LDL cholesterol
   HDL cholesterol
   Triglycerides (oral)     (transdermal)
   Lp(a)
Endothelial cell function
   Prostacyclin
   Nitric oxide
   Endothelin-I
Endothelium-independent
vascular resistance
Homocysteine / -
Insulin sensitivity
li et al. 1997; Imthurn et al 1997) and decreases the level of
ET-1 (Ylikorkala et al. 1995; Wilcox et al. 1997). We should
also keep in mind the vasoconstrictive thromboxane A
2 
(TxA
2
)
,
which is produced by platelets and serves as an endogenous
antagonist of prostacyclin. A shift in the balance between
prostacyclin and thromboxane A
2
 to the prostacyclin domi-
nance may protect against cardiovascular diseases (Mendel-
sohn and Karas 1994).
Estrogen also acts as a calcium antagonist (Collins et al.
1993) and reduces the levels of angiotensin-1 converting-
enzyme in blood (Proudler et al. 1995). Thus estrogen may
cause vasodilatation by mechanisms which operate outside
the vascular endothelium.
The vasodilatory effect of estrogen on blood vessels can
be directly detected by Doppler ultrasound or with a strain-
gauge plethysmography. Indeed, estrogen administration
increases blood flow in aorta (Pines et al. 1991), radial (Lau
et al. 1998; Vehkavaara et al. 2000), carotid and cerebral
arteries (Penotti et al. 1996). It is conspicuous that oral or
transdermal route of administration of estrogen causes simi-
lar vasodilatatory effect in the uterine and carotic arteries
(Cacciatore et al. 1998). It is also noteworthy that both oral
and transdermal HRT decrease systolic daytime blood pres-
sure in normotensive women but have no effect on night
time blood pressure (Cacciatore et al. 2001).
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The biology of vascular endothelium is a complex entity
and presently a target for hectic research. In the above I
have very briefly outlined a few aspects of endothelial re-
search, which have been most clearly linked to the use of
ERT/HRT. For those readers who wish to learn more about
vascular endothelial physiology and cardiovascular diseas-
es, I refer to two current reviews (Vogel 1997; Lind et al.
2000).
2.2.3 Postmenopausal bone loss
Estrogen replacement therapy reduces the rate of bone loss
mainly by decreasing bone resorption (Turner et al. 1994).
In this regard, daily oral doses of 2 mg of estradiol or 0.626
mg of conjugated estrogens daily seem to be equally effec-
tive as daily 50 µg of estradiol from a patch or 1.5 mg estra-
diol from a gel (Compston 1997). Recent studies indicate
that also smaller doses of estrogen may protect bone (Weiss
et al. 1999). Progestin added to ERT has been shown to
potentiate the protective effect of estrogen on bone in some
(The Writing Group for the PEPI Trial 1996), but not in all
studies (Adachi et al. 1997). Data from observational studies
show that ERT decreases the risk of hip fracture by at least
25% (Grady et al. 1992) and vertebral fractures by 50% to
80% (Lindsay et al. 1980; Maxim et al. 1995). In a large pop-
ulation-based case-controlled study the odds ratio for hip
fracture was 0.35 in current users and 0.76 in past users
(Michaëlsson et al. 1998). Furthermore, the bone protective
effect of ERT increases with the duration of use (Moore et al.
1990; Grady et al. 1992), and the initiation of estrogen in late
menopause also reduces the risk of hip fracture (Lindsay
and Tohme 1990).
The generally accepted method for bone mineral density
(BMD) measurement is dual-energy x-ray absorptiometry
(DEXA), and The World Health Organisation criteria for os-
teoporosis are based on this method. However, in order to
detect the rate of bone turnover and to identify patients with
increased bone loss, serial DEXA measurements are needed
at one or two-year intervals. This calls for a need for mark-
ers that show changes in the rate of bone turnover within a
few months. It has also been shown that high bone turnover
is an independent predictor of increased fracture risk (Miller
et al. 1999; Looker et al. 2000). Presently, there is a general
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Table 6.
The most often used bone turnover markers
Formation markers Characteristics
Serum osteocalcin of bone Non-collagenous matrix protein
of bone produced mainly by
osteoblasts, specific marker of
osteoblastic activity
Serum bone-specific alkaline Isoenzyme produced by
phosphatase osteoblasts
Serum carboxyterminal propeptide Propeptide products of type I
of type I procollagen (PICP) collagen formation from
procollagen;
Serum aminoterminal propeptide related to bone matrix formation
of type I procollagen (PINP)
Resorption markers
Urinary hydroxyproline (HOP) Aminoacid, derived from the
breakdown of collagen
Urinary cross-linked aminoterminal Products of osteoclastic
telopeptide of type I collagen (NTx) proteolysis of collagen
Serum cross-linked carpoxyterminal
teleopeptide of type I collagen (ICTP)
Urinary pyridinoline (Pyr) Collagen cross-links holding
collagen molecules together;
Urinary deoxypyridinoline (Dpyr) measuring collagen degradation
consensus that the most valuable biochemical markers of
bone formation are serum bone specific alkaline phosphatase,
osteocalcin, and carboxyterminal propeptide of type I pro-
collagen (PICP), whereas urinary pyridinoline (Pyr), deox-
ypyridinoline (Dpyr), and carboxy- (ICTP) and aminotermi-
nal (NTx) cross-linked telopeptides predict most reliably bone
resorption (Table 6) (Calvo et al. 1996; Miller et al. 1999;
Fink et al 2000; Looker et al. 2000). A large number of stud-
ies have reported significant associations between the levels
of various bone biochemical markers and bone loss rates
(Miller et al. 1999, Fink et al. 2000, Looker et al. 2000).
In conclusion, adequate calcium intake, physical exercice,
and other health measures are naturally of primary impor-
tance in preventing of osteoporosis in postmenopausal wom-
en. ERT/HRT is the first choice of the drugs available for this
purpose. Other options, such as selective estrogen receptor
modulators (SERM´s), bisphosphonates or calcitonin, can be
reserved for more complicated cases.
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2.3 Hazards of estrogen replacement therapy
2.3.1 Breast cancer
ERT/HRT has many health benefits as discussed above, but
its use involves some side effects and hazards, the risk of
breast cancer being the most frightful of those. The recent
meta-analysis of 51 epidemiological studies on 52 705 breast
cancer patients and 108 411 control women showed  that
the relative risk (RR) of getting breast cancer was 1.31 for
current users who had used ERT for 5 to 9 years and 1.58 for
those who had used ERT longer than 15 years (Table 7)
(Collaborative Group on Hormonal Factors in Breast Cancer
1997). The risk of breast cancer increased by 2.3% per year
in current ERT/HRT users. However, this risk of breast can-
cer vanished within five years after the cessation of HRT
(Collaborative Group on Hormonal Factors in Breast Cancer
1997). Finnish Cancer Registry data from 1997 indicate that
2.8% of 50-year old women will develop breast cancer over
the next 10-year period, and the current use of ERT/HRT
increases this proportion to 3.4%. (Table 8). The good news
is that the use of ERT/HRT by women with a familial history
of breast cancer or with reproductive risk factors will not
result in more than simple addition of risk of breast cancer
(Kenemans and Scheele 1997; Scheele et al. 1999).
Duration of use RR
Never 1.00
<1 year 0.99
1-4 years 1.08
5-9 years 1.31
10-14 years 1.24
> 15 years 1.58
Table 7.
The risk of breast cancer in
women who use or have
used ERT/HRT (current
users and users whose last
use < 5 years before diagno-
sis) (according to Collabora-
tive Group on Hormonal
Factors in Breast Cancer
1997)
Duration Number of patients
2 years 1/1000
5 years 3/1000
10 years 7/1000
Table 8.
Excess of patients diagnosed
with breast cancer in
relation to the duration of
ERT/HRT use in Finland
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The mechanisms by which estrogen increases the risk of
breast cancer are not known (Theriault 1996). Moreover, the
impact of the progestin component of HRT on the breast
cancer risk is not clear. Previous data demonstrated that pro-
gestin did not affect the risk of breast cancer caused by es-
trogen only (Collaborative Group on Hormonal Factors in
Breast Cancer 1997), but recent data from Sweden and the
United States showed that progestin increased this risk by
14-40% (Persson et al. 1999; Schairer et al. 2000; Ross et al.
2000; Colditz and Rosner 2000).
In interpreting the data on the risk of breast cancer in
hormone users, we must keep in mind that there are no
placebo controlled, randomized trials on this topic. Thus all
the epidemiological data discussed above are prone to a
number of confounding factors and biases. First, high socio-
economic status is an independent risk factor of breast can-
cer (McPherson et al. 1994), and women belonging to this
group more likely use ERT/HRT (Matthews et al. 1996; Röd-
ström et al. 1999). Second, ERT/HRT users undergo breast
examinations and mammography more frequently than non-
users. This can lead to detection bias; ERT/HRT users are
more likely to be diagnosed with breast cancer than non-
users. The use of estrogen may also favor the development
of cancers with less malignant potential (Gapstur et al. 1999),
which might explain the better prognosis of breast cancer in
patients with ERT/HRT use than in those without ERT/HRT
use (Jernström et al. 1999).
2.3.2 Endometrial cancer
Endometrial cancer is the third commonest cancer in wom-
en in Finland; its incidence was 14.3 in 100 000 women in
1997 (Finnish Cancer Registry 1997). Endogen and exogen
estrogen exposure is one of the risk factors of endometrial
cancer (Franceschi 1989, Grady et al. 1995). Estrogen pro-
motes the formation of estrogen receptors and proliferation
of endometrium whereas progesterone down-regulates these
receptors and causes secretory changes. This explains why
estrogen without the use of progestin leads to an increase in
the risk of endometrial hyperplasia (Kurman et al. 1985).
This can progress to endometrial cancer, albeit only in a
minor part of patients (Grady et al. 1995, Westhoff et al.
2000).
28 2 ESTROGEN REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN
The meta-analysis of 29 epidemiological studies showed a
2.3-fold increase in the risk of endometrial cancer during the
use of unopposed estrogen (Grady et al. 1995). This risk
was higher with a prolonged duration of estrogen use. Less
than one year of use caused a 1.4-fold risk, whereas more
than 10 years of use increased the risk to 9.5-fold. Therefore,
progestin has to be added to ERT in non-hysterectomized
women. Progestin can be administered sequentially or con-
tinuously. The sequential addition of progestin has to be
long enough; an addition of 10 days or more per month
resulted in a RR of 0.9 of endometrial cancer (Voigt et al.
1991) and the interval between progestin phases should be
short enough (Pukkala et al 2001). Thus, in regard to en-
dometrial cancer, estrogen replacement therapy can be safe-
ly used if progestin is added concomintantly.
2.3.3 Venous thromboembolism
The balance between coagulation and fibrinolysis system
determines the risk of thrombosis in a given individual. The
effect of estrogen on this balance is complex. Although ERT/
HRT causes a reduction in the concentration of fibrinogen in
plasma and activates fibrinolysis (Gebara et al. 1995; Conrad
et al. 1997), it increases the risk of venous thromboembo-
lism (Daly et al. 1996, Jick et al. 1996, Grodstein et al. 1996,
Pérez Gutthnn et al. 1997, Hulley et al. 1998, Varas-Lorenzo
et al. 1998). This risk appears to be most pronounced during
the first months of use, and there is no clear dose-depend-
ence of ERT/HRT in this regard (Oger and Scarabin 1999).
Moreover, progestin addition does not modify this risk (Oger
and Scarabin 1999), finding which was confirmed also in the
HERS study. The risk of venous thromboembolism was 2.3
in 1000 woman-years in a placebo group and 6.2 in 1000
woman-years in a hormone treated group (Grady et al. 2000).
Fractures of the hip or other parts of the lower extremity
causing immobilisation, the presence of cancer, and hospi-
talization increased this risk whereas intake of aspirin or
lipid lowering statins decreased it (Grady et al. 2000). Anti-
estrogens, such as tamoxifen and raloxifene, have also in-
creased the risk of thromboembolism from 2 to 5-fold in
randomized trials (Fisher et al. 1998, Cummings et al. 1999),
and in this regard antiestrogens behave similarly to ERT.
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Furthermore, in the study comparing tamoxifen and
toremifene, the incidence of thromboembolic events was
slightly more common in the tamoxifen group (5.9%) than
in the toremifene group (3.5%), but the difference was not
significant (Holli et al. 2000). However, the absolute number
of thromboembolic events in these studies remains low (in
the order of 5 in 1000 women per year), and they are only
seldom fatal. Therefore the risk of thromboembolism is not
a serious concern during the use of ERT/HRT.
2.4 Estrogen replacement therapy in women
with previous breast cancer
Due to the increased incidence and better prognosis of breast
cancer, the number of breast cancer survivors has substan-
tially increased in all western countries during the last two
decades (Garfinkel et al. 1994). The general consensus has
been that these patients should not use ERT/HRT, because
theoretically such use can increase the risk of recurrence
(Marchant 1994; Colditz 1997; Consensus Statement 1998).
However, also these women can suffer from invalidating
menopausal symptoms and certainly become exposed to sim-
ilar postmenopausal health consequences related to estro-
gen deprivation as healthy postmenopausal women. There-
fore, it there is justified reason to ask if a categoric refusal of
ERT/HRT from these women will do more harm than good.
Some non-randomized and mainly retrospective studies
have been conducted on the use of ERT in patients with a
history of breast cancer (Wile et al 1993; Powles et al.1993;
DiSaia et al 1993; Eden et al. 1995; Vassilopoulou-Sellin et al.
1995; Natrajan et al. 1999; Urs˘ic˘-Vrs˘c˘aj and Bebar 1999) (Ta-
ble 9). No excess risk for the recurrence of breast cancer has
been found in these studies.  The number of study subjects
has ranged from 25 to 90 and the mean duration of ERT/
HRT from 15 to 66 months. Naturally, the data are far too
limited to show the final risk or safety of using ERT/HRT in
these patients.
It is obvious that we need randomized, preferably place-
bo-controlled trials to assess the safety of ERT/HRT in breast
cancer survivors. Conducting such trials is problematic. First,
the randomization of breast cancer patients to hormone or
placebo treatment may be ethically questionable at least if a
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Table 9.
Observational studies on the use of hormone replacement
therapy in breast cancer survivors
Source No. of patients Mean duration Recurrences
of use (months, (% / women
range) -year)
Wile et al. 1993 25 35 (6-78) 3 (4%)
Powles et al. 1993 35 15 (1-44) 2 (5%)
DiSaia et al. 1993 77 27 (1-233) 7 (4%)
Eden et al. 1995 90 18 (4-144) 6 (4%)
Vassilopuolou-
Sellin et al.1995 43 31 (24-142) 1 (1%)
Natrajan et al. 1999 50 66 (6-384) 3 (1%)
Urs˘ic˘-Vrs˘c˘aj et al. 1999 21 28 (3-72) 4 (8%)
patient has invalidating hot flushes. This obstacle was ele-
gantly demonstrated in one randomized study where after a
6-month pilot phase, 76% of women randomized to ERT/
HRT group wanted to continue ERT/HRT, whereas 50% of
women randomized to placebo group wanted to swift to
ERT/HRT group (Marsden et al. 2000). Second, alleviation of
hot flushes and/or the occurrence of bleeding and other
consequences of ERT/HRT reveals the code of the regimen
in almost all patients, and thus one goal of randomized pla-
cebo-controlled trial, blinding, is lost. And third, the progno-
sis of breast cancer is presently so good that hundred thou-
sands of such patients would be needed for sufficient statis-
tical power, if the end point of the trial is the recurrence of
cancer.
Sequential or continuous progestin is routinely added to
ERT in non-hysterectomized women for preventing endome-
trial hyperplasia. Recent studies have shown that progestin
may still increase the risk of breast cancer associated with
estrogen (Persson et al. 1999; Schairer et al. 2000; Ross et al.
2000; Colditz and Rosner 2000). The reason for that is un-
clear but the fact that in the breast tissue – on the contrary to
the endometrium – progesterone does not down-regulate
estrogen and progesterone receptors may contribute to this
possible adverse effect (Hargreaves et al. 1998). In fertile
age, the proliferation of breast tissue epithelial cells is higher
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during the luteal phase which is  characterised by high se-
rum progesterone levels (Södergvist 1998). It has also been
shown that in postmenopausal women estrogen combined
to continuous medroxyprogesterone acetate causes signifi-
cantly higher proliferation rate in normal breast tissue than
estrogen alone does (Hofseth et al. 1999). However, we still
need more clinical data to answer the questions whether
estrogen alone is more safe than estrogen + progestin, or
whether there is any difference between sequential and con-
tinuous progestin in regard to the risk of breast cancer re-
currence.
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Figure 5.
The chemical structures of tamoxifen and toremifene
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3.1 Pharmacological and biological characteristics
Tamoxifen and toremifene are non-steroidal triphenylethyl-
ene derivatives with antiestrogenic properties used in the
treatment of breast cancer (Figure 5). Tamoxifen is the cit-
rate salt of the trans isomer of a triphenylethylene compound,
and toremifene is a chlorinated derivative of tamoxifen (Kan-
gas 1990). They are almost completely absorbed after oral
intake, and bioavailability is nearly 100%. Maximal plasma
concentrations of parent compound and metabolites are
reached within 4-7 hours (Buckley and Goa 1989; Wiseman
and Goa 1997). Tamoxifen and toremifene are almost com-
pletly (99%) bound to plasma proteins, mainly to albumin.
They are metabolized in the liver, and the majority of metab-
olites are excreted in the feces (Buckley and Goa 1989; Wise-
man and Goa 1997).
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Tamoxifen and toremifene which are also called selective
estrogen receptor modulators (SERM´s), possess both an es-
trogenic and antiestrogenic activity, depending upon the dose
or target organ (Robinson and Jordan 1989; Wiseman and
Goa 1997). These drugs exert an antitumor activity which is
mediated principally through a specific and competitive in-
hibition of the binding of estrogen to estrogen receptor (Buck-
ley and Goa 1989; Wiseman and Goa 1997). This activity is
very similar for tamoxifen and toremifene (Kangas 1990).
They both prevent the growth of estrogen sensitive cells of
human breast cancer in vitro (Coezy et al 1982; Grenman et
al 1991), but have no effect on the growth of estrogen re-
ceptor negative cell lines (Robinson and Jordan 1989). How-
ever, blocking of estrogen receptors is not the only mecha-
nism of antitumor action, but antiestrogens may operate also
through different growth factors, such as alfa and beta trans-
forming growth factor (Dickson and Lippman 1987; Knabbe
et al. 1987; Colletta et al. 1994) and epidermal growth factor
(Freiss et al.1990). Furthermore, antiestrogens inhibit the
activity of protein kinase C, which is a mediator of some
tumor promoting factors (O´Brian et al. 1985).
3.2 Clinical use of tamoxifen and toremifene
Tamoxifen was introduced more than 20 years ago for the
palliative treatment of advanced breast cancer in postmeno-
pausal women (Buckley and Goa 1989). Since then, tamoxifen
has become the treatment of choice for patients at all stages
of estrogen receptor (ER) positive breast cancer (Early Breast
Cancer Trialists´ Collaborative Group 1998). Fifty-five rand-
omized clinical studies on 37 000 patients with local ER pos-
itive breast cancer have shown that 5 years´ use of adjuvant
tamoxifen reduces the recurrence rate by 47% and the mor-
tality rate by 26% during the 10-year follow-up time (Early
Breast Cancer Trialists´ Collaborative Group 1998).
Although toremifene has been developed later, it com-
petes for favor in the treatment of advanced breast cancer.
Five studies have compared the efficacy of tamoxifen (20,
30, or 40 mg/day) and that of toremifene (40 or 60 mg/day)
in postmenopausal patients with metastatic breast cancer
(Pyrhönen et al. 1999). The overall response rates were 25.3%
and 24.0% for tamoxifen and toremifene, respectively
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(Pyrhönen et al 1999). A complete response was seen in
5.5% of patients treated with tamoxifen and in 7.0% of the
patients treated with toremifene (Pyrhönen et al. 1999). Treat-
ment failure occurred equally soon in the tamoxifen (5.5
months) compared to the toremifene group (4.9 months),
(Pyrhönen et al 1999). These data suggest that tamoxifen 20-
40 mg/day and toremifene 60 mg are equally effective in the
treatment of metastatic breast cancer (Homesley et al. 1993;
Pyrhönen et al. 1997; Pyrhönen et al. 1999). However, more
data on whether tamoxifen (20 mg/day) and toremifene (40
mg/day) are equally effective in the adjuvant treatment of
breast cancer are beginning to appear and the first data on
899 patients with node-positive breast cancer have been re-
cently published (Holli et al. 2000). According to this study
breast cancer recurrence rate was 26.1% in the tamoxifen
group and 23.1% in the toremifene group (p=0.31), and also
the mean time to breast cancer recurrence and overall sur-
vival time was similar in both groups (Holli et al. 2000).
Tamoxifen prevents also the occurrence of new cancers
in the contralateral breast (Early Breast Cancer Trialists´ Col-
laborative Group 1992, 1998). This finding, combined with
the proven efficacy of tamoxifen in the treatment of breast
cancer (Hortobagyi 1998) has led to the rationale to use an-
tiestrogens for breast cancer prevention (Chlebowski et al.
1993). Indeed, tamoxifen decreased the incidence of inva-
sive breast cancer by 49% in one large, randomized, place-
bo-controlled study (Fisher et al. 1998) but not in two other
studies with smaller number of participants (Powles et al.
1998, Veronesi et al. 1998). The newer SERM´s, such as e.g.
raloxifene, appear also effective in the prevention of breast
cancer, because raloxifene decreased the risk of breast can-
cer by 76% during the three years of use in older postmeno-
pausal women with osteoporosis (Cummings et al. 1999).
All this implies that antiestrogenic compounds may have a
place also in the prevention of breast cancer in future.
3.3 Gynecological consequenses of antiestrogens
Tamoxifen and toremifene have both antiestrogenic and es-
trogenic activity, which are briefly summarized in table 10.
Therefore, the whole impact of their intake on woman body
and life is complex. They cause and aggravate vasomotor
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Table 10.
Antiestrogenic and estrogenic effects of tamoxifen and toremifene in
postmenopausal women
Antiestrogenic Estrogenic
Gonadotropins FSH
LH
Gynecologic organs Vasomotor symptoms Karyopycnotic index
Endometrial hyperplasia
Endometrial polyps
Endometrial cancer
Breast tissue ER-positive breast cancer
tissue proliferation
Cardiovascular system Risk of myocardial infarction
Total cholesterol
LDL cholesterol
HDL cholesterol    /-
Lipoprotein (a)
Vasodilatation
Risk of venous thrombosis
Bone Rate of bone loss
symptoms in postmenopausal women, although they reduce
blood levels of FSH and LH (Jordan et al. 1987; Ellmén et al.
2000). Tamoxifen causes also maturation of the vaginal epi-
thelial cells and increases their karyopyknotic index (Lahti
et al. 1994). Both tamoxifen and toremifene cause the prolif-
eration of the endometrium and increase the risk of endome-
trial polyps and hyperplasia (Tomas et al. 1995), and these
changes are dependent on the duration of tamoxifen use
(Cohen et al. 1999). The worst complication of tamoxifen
use can be endometrial cancer. Tamoxifen treatment has been
associated with a 4.1 to 7.5-fold relative risk of developing
endometrial carcinoma in two extensive studies (Fisher et al.
1994; Rutqvist et al. 1995). These data were confirmed in a
meta-analysis on 55 adjuvant tamoxifen trials with altogeth-
er 37 000 breast cancer patients; the risk of endometrial can-
cer was doubled by 1 or 2 years use of tamoxifen, and ap-
proximately 4-fold after the use of 5 years of tamoxifen (Ear-
ly Breast Cancer Trialists´ Collaborative Group 1998). There
are also some data which link tamoxifen to the formation of
ovarian cysts and endometriomas, but this evidence is not
so strong that it could be regarded as well established so far
(Neven et al. 1993; Cohen 1993).
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In view of rather similar pharmacology and clinical profile
of tamoxifen and toremifene, it is likely that toremifene causes
similar estrogenic effects in the female body as does
tamoxifen, although some authors have questioned it (Wise-
man and Goa 1997). In some animal studies toremifene has
caused fewer tumours in the liver than tamoxifen (Hirsimäki
et al 1993), reflecting perhaps a weaker estrogenic effect. It
is not known if the estrogenic activities of tamoxifen and
toremifene are similar in human, and therefore more clinical
comparative data are needed.
3.4 Antiestrogens and cardiovascular organs
Cardiovascular system seems to be a target tissue for estro-
gen and an important issue is to clear up the role of anties-
trogen in the cardiovascular organs. In a Scottish adjuvant
trial tamoxifen reduced the occurrence of myocardial infarc-
tion by 50% in 5 years (McDonald et al. 1995). This benefit
may be mediated in part through the falls in total cholesterol
and low-density lipoprotein (LDL) cholesterol (Love et al.
1994; Grey et al. 1995). Also toremifene reduces total cho-
lesterol and LDL cholesterol levels (Gylling et al. 1995; Saar-
to et al. 1996). As regards the cardioprotective high-density
lipoprotein (HDL) cholesterol, tamoxifen reduced it by 5%
whereas toremifene increased it by 14% (Saarto et al. 1996).
Both tamoxifen and toremifene decreased the level of lipo-
protein (a) (Saarto et al.1996) which is a cholesterol-inde-
pendent risk factor of ischemic heart disease. Tamoxifen also
reduced the level of fibrinogen (Love et al. 1994) and that of
homocysteine (Anker et al. 1995), which effects may also
contribute to cardiovascular protection.
All these effects may be related to the estrogenic activity
of tamoxifen and toremifene. In contrast no data exist so far
on whether antiestrogens could trigger a direct dilatation in
the arteries or affect the endothelial factors, such as prostag-
landins, NO, or ET-1.
373 TAMOXIFEN AND TOREMIFENE
3.5 Antiestrogens and bone
Because antiestrogens are given often for 5 or more years in
postmenopausal women as an adjuvant therapy of breast
cancer, it is important to know also their effect on bone
integrity which, on the other hand, is already affected by
postmenopausal hypoestrogenism. Tamoxifen has been
shown to increase bone mineral density in postmenopausal
women by 1-2% per year (Grey et al. 1995; Powles et al.
1996; Chang et al. 1996). However, so far we do not have
any epidemiological data on the risk of hip and other frac-
tures during tamoxifen use.
Tamoxifen has been shown to reduce bone resorption as
measured by the output of hydroxyproline (Ward et al.1993),
pyridinoline, and deoxypyridinoline (Kenny et al. 1995), and
also bone formation measured by bone-specific alkaline
phosphatase and osteocalcin (Kenny et al. 1995).
The data on the effect of toremifene on bone are scanty.
Yet in one comparison tamoxifen (20 mg/day) and toremifene
(60 mg/day) used for two years did not decrease BMD, where-
as the addition of bisphosphonate clodronate to antiestro-
gens increased BMD by 2-4% (Saarto et al. 1997).
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III  AIMS OF THE STUDY
The objectives of the present study were to
1. evaluate the effects and safety of estrogen replacement
in postmenopausal women with a history of breast
cancer (publication I)
2. assess and compare the gynecological consequences of
tamoxifen and toremifene (publication II)
3. explore some biological mechanisms dealing preferably
with endothelial cells during the use of tamoxifen and
toremifene (publications III and IV)
4. compare the effects of tamoxifen and toremifene on bone
metabolism and density (publications V and VI)
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IV PATIENTS AND METHODS
1 PATIENTS
The study population which was collected with the permis-
sion of the local ethics committee,  consisted of two patient
groups: first, 131 women with a history breast cancer seek-
ing a relief for menopausal symptoms (=ERT group) and
second, 167 women who started either tamoxifen or
toremifene as an adjuvant treatment for stage II-III breast
cancer (=Tam/Tor group) (Table 11). All patients were post-
menopausal as seen from the passage of more than 6 months
from last menstruation and/or from serum FSH level being
higher than 30 IU/L.
Table 11.
Patient series in publications I-VI
I II III IV V VI
No. of 131 167 38 44 30 30
patients (88 ERT, (84 tam, (17 tam, (25 tam, (16 tam, (15 tam,
(treatment) 43 control) 83 tor) 19 tor) 19 tor) 14 tor) 15 tor)
Age (years, 55±5.8 62.8±8.4 60.3±8.4 61.7±7.1 59.7±8.6 61.5±2.6
mean±SD)
BMI (kg/m2, 24.2±2.8 27.2±0.3 26.2±4.4 25.9±3.0 25.9±3.8 26.3±4.0
mean±SD)
Follow-up 2.5 yrs 2.3 yrs 6 months 12 months 12 months 12 months
time
Main Endometrial Recurrences, Urinary Plasma BMD BMD,
parameters safety, climacteric prostacyclin endothelin-I hydroxyproline pyridinoline
studied relief of symptoms, and and nitrate ICTP, NTx, deoxypyridin-
climacteric endometrial thromboxane bone alkaline oline
symptoms, findings phosphatase,
recurrences osteocalcin
PINP, PICP
(ERT=estrogen replacement therapy, tam=tamoxifen, tor=toremifene, BMD=bone mineral density,
ICTP=cross-linked carboxyterminal telopeptide of type I collagen, NTx=cross-linked aminotermi-
nal telopeptide of type I collagen, PINP=aminoterminal propeptide of type I procollagen,
PICP=carboxyterminal propeptide of type I procollagen)
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Table 12.
Clinical characteristics of breast cancer patients scheduled to
start estrogen alone (ERT) or combined with progestin (HRT) or
who were followed as controls
Variable Women with Controls p-value
ERT/HRT
Number of patients 88 43
Age at diagnosis 49±6.8 48±7.4 NS
(mean±SD)
Classification of
tumor spread
Size NS
Ductal in situ 3 (3.4%) 1 (2.3%)
< 2 cm 67 (76.1%) 29 (67.4%)
2-5 cm 17 (19.3%) 11 (25.6%)
< 5 cm 1 (1.1%) 2 (4.7%)
Axillary nodes <0.05
N0 72 (81.8%) 30 (69.8%)
N1 10 (11.4%) 13 (30.2%)
Not analyzed 6 (6.8%) 0 (0%)
Estrogen receptors NS
Detectable 57 (64.8%) 29 (67.4%)
Undetectable 15 (17.0%) 9 (20.9%)
Not analyzed 16 (23.9%) 5 (11.6%)
Progesterone receptors NS
Detectable 54 (61.4%) 30 (69.8%)
Undetectable 13 (14.8%) 7 (16.3%)
Not analyzed 21 (23.9%) 6 (13.9%)
Histologic grade NS
Ductal in situ 3 (3.4%) 1 (2.3%)
Gr I 37 (42.0%) 12 (27.9%)
Gr II 28 (31.8%) 15 (34.9%)
Gr III 12 (13.6%) 7 (16.3%)
Not known 8 (9.1%) 8 (18.6%)
1 PATIENTS
The patients in the ERT group were submitted by oncolo-
gists, surgeons, general practitioners, or gynecologists for
gynecological consultation because of incapacitating climac-
teric symptoms (Table 11, Table 12).  They had been operat-
ed on for a mean of 4.2 years (range 1 month to 20 years)
before, when still 54 women (41%) had been at premeno-
pausal age. Sixty-two patients (47%) had experienced radi-
cal mastectomy and 69 patients a breast-sparing operation.
Axillary nodes were dissected in all except 6 women. One
hundred patients had received postoperative radiotherapy
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and 19 patients adjuvant chemotherapy. Five patients had
used antiestrogens but stopped it 3 to 5 years before the
initiation of the trial. Forty-three women were hysterect-
omised. Before the start of ERT/HRT, all patients underwent
gynecological examinations (e.g. mammography, pelvic ex-
amination, Pap smear collection), and the benefits and risks
of ERT/HRT were explained thoroughly orally and in writ-
ten form, and all patients gave their written consent.
The patients of Tam/Tor group were referred to gyneco-
logical follow-up after they had been  randomized at the
department of oncology to receive either tamoxifen (20 mg/
day) or toremifene (40 mg/day) for three years (Table 11).
They were participants in the Finnish Breast Cancer Group
Adjuvant Toremifene versus Tamoxifen Trial, and randomi-
zation was done by Finnish Cancer Register. Fifty-six pa-
tients had experienced conservative surgery and 111 patients
mastectomy 6 to 8 weeks before the start of antiestrogens,
and axillary nodes were dissected in all women. In addition,
all women had received postoperative local radiotherapy.
Thirty-eight patients were hysterectomized, 53 used antihy-
pertensive drugs, and 27 smoked.
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2 STUDY TREATMENTS
In the study I, 88 of 131 women (67%) admitted because of
climacteric symptoms finally started the use of ERT/HRT (Fig-
ure 6). Hysterectomized patients (n=33) used 2 mg of oral
(Progynova®, Schering, Berlin, Germany) (n=31) or 1.5 mg
transdermal estrogen (Estrogel®, Leiras, Turku, Finland) (n=3).
Non-hysterectomized patients received, in addition of oral
(44 patients) or transdermal estrogen (10 patients), sequen-
tial medroxyprogesterone acetate (10 mg/day, for 10 days in
each month, Provera®, Pharmacia & Upjohn, Kalamazoo,
Michigan) (Figure 6).
No (n=43)
Reasons for refusal
- premenopausal (n=6)
- only mild climacteric symptoms,
no risks of cardiovascular diseases
or osteoporosis (n=17)
- fear of recurrence (n=20)
Visits 3 -> :  Follow-up visits
- measurement of weight, height, blood pressure
- pelvic examination
- Pap smear collection
- ultrasound examination of uterus, endometrium and ovaries
- rating of menopausal symptoms
Visit 1: Recruitment (n=131)
- clinical examination, FSH measurement
- oral and written information
Visit 2: Patient´s decision on the start of ERT/HRT
Yes (n=88)
- oral estrogen (n=31)
- transdermal estrogen (n=3)
- oral estrogen+sequential oral
progestin (n=44)
- transdermal estrogen+sequential
oral progestin (n= 10)
Figure 6.
Design of the trial to assess the value of hormone replacement
(ERT/HRT) in patients with breast cancer (Study I)
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In the study II, 84 patients used tamoxifen (20 mg/day,
Tadex®, Orion, Turku, Finland) and 83 used toremifene (40
mg/day, Fareston®, Orion, Turku, Finland). The follow-up
times of both study group are presented in Table 13.
Table 13.
Follow-up times completed by patients using either estrogen or
estrogen + sequential progestin (ERT/HRT), or tamoxifen (Tam)
or toremifene (Tor)
Time ERT/HRT Tam Tor
(n=88) (n=84) (n=83)
< 1 year 12
1-2 years 20 23 14
2-3 years 20 19 17
3 years or more 36 42 52
3 METHODS
3.1 Clinical examinations and follow-up
Clinical examinations including measurements of weight,
height, and blood pressure, as well as pelvic examination
and Pap smear collection were performed in all patients
before the start of hormone treatment. The same examina-
tions were repeated 6 and 12 months later and then annual-
ly. Blood and urinary samples were collected after the over-
night fast before the start of hormone regimens and at 6 and
12 months of treatment. Serum, plasma, and urinary samples
were stored at -22°C until assayed. Before the sampling, pa-
tients were instructed to avoid nitrate-rich (meat, fish, green
vegetables, malt beverages and wine) and gelatin containing
(meat, fish, poultry, yoghurt and pudding) food for 48 hours.
The patients recorded menopausal symptoms (hot flush-
es, sweating, sleep disturbance, nervousness, depression,
vertigo, fatigue, arthralgia, headache, tachycardia and vagi-
nal dryness) on the modified Kupperman scale at each visit
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(Wiklund et al. 1992). The severity of each symptom was
graded form 0 to 3, and the severity score for hot flushes
was multiplied by 4 and that for sweating, sleep disturbance,
and nervousness by 2, and the scores were summed up.
The patients were followed  at the oncological or surgical
departments in regard to the status of breast cancer. The
breasts were carefully palpated at each visit, and mammog-
raphy was performed annually. In addition, the serum level
of CA 15-3, reflecting a possible growth or recurrence of
breast cancer, was assessed at each visit.
3.2 Transvaginal sonography and endometrial
sampling
Transvaginal sonography (Aloka SSD 500) was performed at
each visit to assess gynecological organs including the en-
dometrial thickness. Sonographic examination was comple-
mented by saline sonohysterography (Widrich et al. 1996), if
endometrial polyp was suspected (study I and II) or en-
dometrial thickness exceeded 8 mm (study II). In patients
with endometrial polyp diagnosed by saline sonohysterog-
raphy, polyp was removed with electroresector through hys-
teroscopy.
To assess the blood flow in the uterine artery, pulsatility
index (PI) was measured by using doppler ultrasound (Hi-
tachi 515A, Tokyo, Japan, 6.5 MHz endovaginal transducer)
before the start of medication and at 6 and 12 months of trial
in 30 patients using either tamoxifen (n=15) or toremifene
(n=15) (Study II).
Endometrial biopsy was collected with Pipelle endometri-
al aspirator (Unimar, Wilmington, CN) (Chambers and Cham-
bers, 1992) from patients with intact uterus,  in the study I if
endometrial thickness exceeded 5 mm at entry or 10 mm on
a follow-up visit, or if there was abnormal uterine bleeding
before recruitment or during the trial. Endometrial biopsy
was collected at each visit in the trial II. The endometrium
was classified as atrophic (small simple tubular glands lined
by cuboidal epithelium, the nuclei centrally located, no mi-
toses) or mildly proliferative (small tubular glands lined by
cuboidal to columnar epithelium, ovoid nuclei basally or
centrally located, some mitoses). The same experienced pa-
thologist (Dr. T. Wahlstöm) studied all histological samples.
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3.3 Laboratory measurments
The serum concentration of FSH was measured by time-re-
solved fluoroimmunoassay (DELFIA; Wallac, Turku, Finland)
according to the instructions of the manufacturer. Tumor
marker CA 15-3 was measured by immunoradiometric assay
(O´Hanlon et al. 1995).
Prostacyclin and thromboxane output were assessed by
their stable urinary metabolites 2,3-dinor-6-keto prostaglan-
din F
1 a
 and 2,3-dinor-thromboxane B
2
, respectively, by radi-
oimmunoassays after solid-phase extraction and purification
of the sample by high-performance liquid chromatography
(Ylikorkala et al. 1986, Tulppala et al. 1991). To avoid the
effect of differences in the dilution of urine, excretions were
expressed against creatinine, which was measured by a rou-
tine laboratory method. The capacity of platelets to produce
TxA
2
 was assayed by measuring the serum concentration of
TxB
2
, a metabolite of TxA
2,
 by specific radioimmunoassay
(Viinikka and Ylikorkala 1980). Before measurement, blood
samples were allowed to clot at +37°C for 30 minutes and
serum was then separated. The intra-assay coefficient of var-
iation in measurements of prostacyclin and thromboxane
metabolites was less than 8%, and the interassay coefficient
of variation was between 10.4-14.1%.
Plasma endothelin-1 was analyzed by radioimmunoassay
(Ylikorkala et al. 1995). Acidified 3 ml plasma samples were
extracted with Sep-Pak-Vac tC18 cartidges. After washes with
0.1% trifluoroacetetic acid (TFA) and 45% methanol-0.1% TFA,
ET-1 was eluted with 90% methanol-0.1% TFA. The evapo-
rated samples were dissolved in 0.45 ml of assay buffer (50
mmol/l phosphate buffer, pH 7.4, 150 mmol/l NaCl 1% bo-
vine serum albumin). The radioimmunoassay was performed
in tubes coated first with goat anti-rabbit immunoglobulin
and then with diluted ET-1 antibody raised in rabbits. The
samples were incubated for 24 hours and then with 10000
dpm of 125I-ET-1 for 48 hours. The bound radioactivity re-
maining in tubes after washing was counted, and the results
calculated on the basis of a dilution series of authentic ET-1.
The intra-assay coefficient of variation for measurement was
5.7%.
Nitric oxide production was evaluated on the basis of the
concentration of nitrate+nitrite (NOx). Nitrate was reduced
to nitrite by nitrate reductase, the sample deproteinized with
ZnSO
4
, and the concentration of nitrite was measured by the
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spectrophotometrically based Griess reaction (Ylikorkala et
al. 1998). The intra-assay coefficient of variation of NOx was
1.7% and 2.2% in the lower and higher concentration range,
respectively.
Bone resorption markers
Urinary hydroxyproline (HOP) was measured with high-per-
formance liquid chromatography (Turpeinen and Pomoell
1985). The intra-assay coefficient of variation of this method
was 8.9%. Urinary cross-linked aminoterminal telopeptide
of type I collagen (NTx) was measured with an enzyme-
linked immunosorbent assay using monoclonal antibody di-
rected against th N-telopeptide of type I collagen isolated
from human urine (Hanson et al. 1992). The intra-assay var-
iation of this method was 6.2%. To avoid errors caused by
differences in urine dilution, both HOP and NTx data were
expressed against creatinine assessed by a routine laborato-
ry method. Serum cross-linked carboxyterminal telopeptide
of type I collagen (ICTP) was determined by radioimmu-
noassay (Telopeptide ICTP, Orion Diagnostica, Espoo, Fin-
land) (Risteli et al. 1993), and the intra-assay coefficient of
variation for this measurement ranged from 3% to 9%. Uri-
nary excretion of pyridinoline (Pyr) and deoxypyridinoline
(Dpyr) was measured by ion-pair reversed-phase high per-
formance liquid chromatoraphy (RP-HPLC) (Garnero et al.
1994). To avoid any effect of different dilutions of urine, Pyr
and Dpyr data are expressed against grams of creatinine.
The intra-assay coefficient of variation is less than 10% for
Pyr and less than 15% for Dpyr.
Bone formation markers
Bone-specific alkaline phosphatase in serum was measured
by immunoradiometric assay (Tandem-R Ostase, Hybritec
Europe, Liege, Belgium) (Epstein 1988). The intra-assay var-
iation in this method was below 7%. Serum osteocalcin  was
measured by an immunoradiometric assay using antibodies
against human osteocalcin (Osteocalcin FEIA, Farmacia CAP
System, Uppsala, Sweden) (Epstein 1988). The intra-assay
coefficient of variation was 7%. Serum aminoterminal (PINP)
and carboxyterminal (PICP) propeptide of type I procolla-
gen were determined by RIA (Procollagen Intact PINP RIA
Kit, Procollagen PICP RIA Kit, Orion Diagnostica) (Melkko
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et al. 1996). The intra-assay coefficient of variation of the
measurement of PINP was 5-8% and for measurement of
PICP 3%.
3.4 Bone density measurement
Bone mineral density (BMD) in the lumbar spine (LI-IV) and
in different sites of the proximal femur was measured by
dual-energy x-ray absorptiometry (DEXA) (Hologic QDR-
1000, Waltham, MA) (De Boer et al. 1994). Data were given
as density against area (g/cm2). The intra-assay coefficient of
variation in our department was 0.5% in lumbar spine and
1% in femoral neck.
3.5 Statistical analyses
All data are expressed as a mean ± standard deviation (SD)
(Studies I-III ) or standard error (SE) (Studies IV and VI). The
significance of differences between the groups with numer-
ical variables was determined with paired and unpaired
Student´s t-test. When repeated measures were obtained, the
two-way analysis of variance (ANOVA) was used. The com-
parison of two proportions in case of paired samples was
performed by McNemar´s test in study II. Chi-square test
was used to compare the distribution of categorical varia-
bles of two independent samples (Studies I and II). Pearson
coefficient (study IV) or Spearman nonparametric correla-
tion analysis (study V, VI) were used for the determination
of correlation between the two variables.
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V  RESULTS
1 ESTROGEN REPLACEMENT
THERAPY IN BREAST CANCER
PATIENTS (Study I)
The mean follow-up time with estrogen regimen was
2.5±1.5 years (range 1 month to 5.2 years), which corre-
sponds to 216 woman-years. Forty-three women were fol-
lowed as control population without estrogen regimen for a
mean of 2.5±1.3 years (range 1 month to 4.6 years) (= 111
woman-years). Ten of the 88 patients discontinued estrogen
treatment within the 12 to 39 months; four because of lack
of climacteric symptoms and six because of recurrence of
disease or new breast cancer. One woman with contralateral
breast cancer wanted to continue ERT/HRT. Five patients
needed to increase the dose of oral estradiol to 3 mg be-
tween 6 and 12 months for sufficient alleviation of symp-
toms, and three women reduced the dose from 2 to 1 mg
between 1 and 4 months because of breast tenderness.
Three women with sequential regimen experienced PMS-
like symptoms during progestin phase, and these women
subsequently took progestin courses at two-month intervals.
ERT/HRT abolished or alleviated vasomotor or other cli-
macteric symptoms (Figure 7). Forty-seven patients with in-
tact uterus had regular withdrawal bleeding, seven patients
had spotting, and seven patients did not bleed al all. None
discontinued the treatment because of adverse effects. Two
women had transient simple endometrial hyperplasia after
one and two years of the regimen.
Five of 88 patients using ERT/HRT experienced the recur-
rence of the cancer after a mean of 19 months (range from
12 to 36 months) use of ERT/HRT, and two developed con-
tralateral breast cancer after 14 and 24 months use of ERT/
HRT, respectively. All the recurrences or contralateral breast
cancers were detected as a consequence of clinical symp-
toms,  Ca 15-3 levels was of no help to predict these cases.
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Figure 7.
Kupperman indexes (mean+SD) before and at 6 and 12 months of
estrogen replacement in 76 patients with a history of breast
cancer
a) p<0.0001 compared to initial
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In control population, four women had a relapse of cancer
and one woman got contralateral breast cancer. The recur-
rence rates (%/woman-year) in ERT-users and non-users
were 3.0% and 4.0%, respectively.
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Figure 8.
The rate of vasomotor and vaginal symptoms before and during
first year use of tamoxifen (grey bars) or toremifene (white bars)
in 167 patients with a history of breast cancer
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(Studies II-VI)
A total of 167 patients completed a mean of 2.3±0.8 years of
follow-up. Thirty-seven patients discontinued the follow-up,
17 (11 in the tamoxifen group, six in the toremifene group)
because of the failure to report at research center according
to the protocol, five patients (three in the tamoxifen group,
two in the toremifene group) because of adverse effects,
and 15 patients (seven in the tamoxifen group, eight in the
toremifene group) because of recurrence of breast cancer.
Vasomotor symptoms and vaginal irritation were the most
common adverse events during antiestrogen use, and in this
regard tamoxifen and toremifene did not differ from each
other. (Figure 8). Vaginal bleeding occurred in 13 patients
(five in the tamoxifen group, eight in the toremifene group).
In these patients, endometrial polyps were detected in four
patients, endometrial proliferation in eight patients, and one
patient had atrophic endometrium.
Small uterine fibroids were detected in 28 patients, but
neither tamoxifen nor toremifene caused any growth of these
tumors or appearance of new fibroids. Simple ovarian cysts
were detected in four women starting toremifene, but they
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disappeared spontaneously during the first 6 months. One
ovarian thecoma diagnosed after one-year use of tamoxifen
was removed laparoscopically. Before the start of antiestro-
gens, five patients suffered from symptoms of partially pro-
lapsed uterus, and vaginal hysterectomy was performed in
these patients during the trial. Pap smears showed no pre-
malignant lesions before or during the trial in any patient.
2.1 Endometrial findings (Study II)
Endometrial thickness increased significantly during both
regimens already during the first six months, and no further
thickening was seen after one year (Figure 9).  Before the
start of antiestrogen regimen, an adequate endometrial sam-
ple was obtained in 94 of 129 (73%) patients with intact
uterus. The sampling did not succeed in 25 women (19%)
due to cervical stenosis and in 10 women (8%) due to intol-
erable pain. Endometrium was atrophic in 71 patients, where-
as 19 patients showed proliferative endometrium; 16 of these
had used estrogen replacement before the diagnosis of breast
cancer. Four polyps (1 in tamoxifen group, 3 in toremifene
group) were detected before the start of antiestrogen regi-
men.
Figure 9.
Endometrial thickness (mean+SD) in breast cancer patients using
either tamoxifen (grey bars) or toremifene (white bars)
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Figure 10.
Endometrial findings during the first 3 years use of tamoxifen
(grey bars) or toremifene (white bars). In addition, one patient
had endometrial carcinoma at one year of toremifene use and one
patient had endometrial breast cancer metastasis at two years of
tamoxifen use.
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During the control visits, endometrial sampling succeed-
ed in 81% of patients. Proliferative endometrium was seen in
46.8% of samples in tamoxifen users and in 32.2% of sam-
ples in toremifene users (p<0.0001 between groups) (Figure
10). From the 24 polyps diagnosed during the antiestrogen
regimen, 17 existed in tamoxifen users and seven in
toremifene users (p<0.05). All polyps detected before and
during  the antiestrogen regimen were removed hysteroscop-
ically. One patient on toremifene developed endometrial
carcinoma at 12 months and she also had a metastasis of
breast cancer in her ovary. One patient got breast cancer
metastasis on her endometrium after 24 months of tamoxifen
use.
2.2 Vascular effects
2.2.1 Uterine artery resistance (Study II)
Tamoxifen did not have any effect on uterine artery resist-
ance, but toremifene reduced it significantly (p<0.05) by 12
months. The changes in PI or endometrial thickness did not
correlate with each other in the whole series or in either
subgroup.
2.2.2 Prostacyclin and thromboxane
Neither tamoxifen (n=15) nor toremifene (n=19) caused any
change in the production of prostacyclin or thromboxane A
2
(Figure 11). Before the start of the antiestrogen regimen,
patients using antihypertensive drugs had lower urinary pros-
tacyclin metabolite (dinor-6-keto) level (18.5±6.1 vs 35.5±18.5
ng/mmol, p<0.05) and also lower platelet capacity to pro-
duce thromboxane A
2
 (62.6±67.8 vs 134.6±75.6 ng/mL,
p<0.05) than did the normotensive patients.
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2.2.3 Endothelin-1 and nitrite/nitrate (Study IV)
Toremifene reduced the level of endothelin-1 (ET-1) by 12.9%
at 6 months (p<0.01) and a similar fall was also seen at 12
months, whereas tamoxifen did not cause any change in ET-
1 level (Figure 12). The changes in ET-1 at 12 months during
the antiestrogen regimen were dependent on baseline ET-1
level (r=0.49, p=0.0008). Antiestrogens failed to affect the
levels of plasma nitrite/nitrate, but the ratio between nitrite/
nitrate and ET-1 rose by 31.6% (p<0.05) at 6 months and by
35.6% (p<0.05) at 12 months of the use of antiestrogens.
Figure 11.
Urinary excretion of the metabolites of prostacycylin (2,3-dinor-6-
ketoprostaglandin F
1 a
, dinor-6-keto) and thromboxane A
2
 (2,3-
dinor-thromboxane, dinor-TxB
2
) before and at 6 months of
regimen with tamoxifen (n=17, grey bars) or toremifene (n=21,
white bars)
Figure 12.
Plasma levels of endothelin-1 before and at 6 and at 12 months of
treatment with tamoxifen (n=25, grey bars) or toremifene (n=19,
white bars)
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2.3 Bone (Studies V and VI)
Bone resorption
Both tamoxifen and toremifene reduced urinary output of
NTx at 6 and 12 months (Figure 13). Urinary Pyr and Dpyr
decreased significantly at 6 months during both regimens,
but after 12 months of treatment Pyr and Dpyr were signifi-
cantly decreased only in women using tamoxifen (Figure
13). No significant changes were seen in the other variables
for bone resorption.
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Figure 13.
Changes in bone resorption markers during tamoxifen (grey bars)
or toremifene (white bars) use, a)p<0.01, b)p<0.05 in patients
with breast cancer
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Figure 14.
Changes in bone formation markers during tamoxifen (grey bars)
or toremifene (white bars) regimen
a) p<0.01
b) p<0.05
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Bone formation
Tamoxifen caused a significant fall in osteocalcin, PINP, and
PICP, whereas toremifene did not cause any change in these
(Figure 14). Neither tamoxifen nor toremifene caused any
changes in bone-specific alkaline phosphatase or ICTP.
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Figure 15.
Changes in BMD during one year with tamoxifen (grey bars) or
toremifene (white bars) in 30 patients with a history of breast
cancer (Study V)
a) p<0.05 compared to initial
-4
-2
0
2
4
6
8
Lumbar             Femoral         Throchanteric    Ward´s
spine                 neck               region                triangle
a
 a
Ch
an
ge
 in
 B
M
D 
(%
)
Bone mineral density
Tamoxifen was accompanied by increases in BMD in the
lumbar spine (0.4-2.0%), in femoral neck (0.7-1.0%), and in
Ward´s triangle (2.8-5.0%). Toremifene did not cause any
change in BMD or tended to slightly decrease it (Figure 15).
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Figure 16.
Correlation between the changes in cross-linked aminoterminal
telopeptide of type I collagen (NTx) (at 6 months) and in bone
mineral density (BMD) (at 1 year) in 30 patients with a history of
breast cancer and with current use of antiestrogens
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Correlation between changes in bone biochemistry and in
BMD
The fall in NTx predicted most accurately the change in BMD;
the falls in urinary NTx at 6 months correlated significantly
with changes in the lumbar spine BMD (r=-0.58, p<0.001) in
the whole patient series (Figure 16).
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One in ten Finnish women will be diagnosed with breast
cancer during her lifetime (Finnish Cancer Registry 1997).
Nowadays breast cancer is diagnosed in an earlier phase
perhaps as a consequence of mammographic screening pro-
grams (Garfinkel et al. 1994; Garne et al. 1997; UK Trial of
Early Detection of Breast Cancer Group 2000), and also the
treatment of breast cancer has improved (Early Breast Can-
cer Trialists´ Collaborative Group 1992, 2000). Therefore, in
spite of the 100% rise in incidence from the beginning of
1970ies, the absolute breast cancer mortality has not increased
(Finnish Cancer Registry 1997, Statistics Centrum of Finland;
Peto et al. 2000). Therefore clinicians see nowadays increas-
ing  numbers of women who have survived their breast can-
cer.  Because of the possible role of estrogen in the etiology
of breast cancer, it has been thought that ERT/HRT can trig-
ger the recurrence of breast cancer, and therefore a history
of breast cancer has been regarded as a rather absolute con-
traindication for ERT/HRT (Marchant 1994; Colditz 1997;
Consensus Statement 1998). However, the rationale of this
denial has been questioned (Cobleigh et al. 1994; Braendle
1998) because the prognosis of breast cancer is presently so
good that most women with a history of breast cancer may
die from other diseases than breast cancer. One factor con-
tributing to improved prognosis of breast cancer is the use
of antiestrogens (Early Breast Cancer Trialists´ Collaborative
Group 1992, 1998). This effect must be mediated through
antiestrogenic effect in the breast cancer tissue (Buckley and
Goa 1989; Wiseman and Goa 1997), but in some other tis-
sues and organs antiestrogens, for example tamoxifen, have
estrogenic effects (McDonald et al. 1995; Grey et al. 1995;
Powles et al. 1996; Chang et al 1996). Furthermore, the risk
of endometrial cancer has been reported to increase during
the long-term use of tamoxifen (Early Breast Cancer Trial-
ists´ Collaborative Group 1998) which can also be seen as
one sign of estrogenic effect. On the other hand, tamoxifen
causes or worsens typical menopausal vasomotor symptoms
(Buckley and Goa 1989).Toremifene is a newer antiestro-
genic compound which has similar antiestrogenic activity
on breast cancer tissue to tamoxifen (Pyrhönen et al. 1999),
60 VI DISCUSSION
but so far little has been known about the estrogenic conse-
quences of toremifene.
In this study, it has been evaluated the usefulness and
safety of ERT/HRT and compared the gynecologic and other
consequences of tamoxifen and toremifene in postmeno-
pausal breast cancer patients.
I studied 131 postmenopausal patients with breast cancer
seeking help for menopausal symptoms. From those, 108
women had a sound indication for using ERT/HRT, and 88
patients finally started ERT/HRT. Forty-three women who
did not start ERT/HRT were followed as a control group. All
patients were carefully examined at the oncological depart-
ment before being included in the trial to ensure that none
had any recurrence at recruitment. Similar oncological ex-
aminations (mammography, tumor marker CA 15-3 meas-
urement) were annually repeated during the trial to detect
any possible recurrences as soon as possible. The history of
breast cancer denotes a 1.5- to 2-fold risk of endometrial
cancer in these women (Adami et al. 1997). Therefore en-
dometrium was assessed by serial histological samples and
ultrasonography.
The use of estrogen effectively alleviated climacteric symp-
toms in these patients. This was expected because no data
imply that this effect of ERT/HRT should be different in these
patients. A high continuation rate (88.4%) of ERT/HRT pro-
vides an additional proof of the good efficacy of ERT/HRT
in the control of vasomotor symptoms, although the chance
to see always the same gynecologist, often after a very short
notice, may have contributed to the high compliance.
The overall risk of recurrence or contralateral breast can-
cer was similar in patients with (3%) or without ERT/HRT
(4%). This result is in line with previous data showing no
excess risk of relapse during 2-3 years of use of ERT/HRT
(Table 14). Furthermore, although breast cancer per se indi-
cates an increased risk of endometrial cancer (Adami et al.
1997), no primary endometrial cancer developed during the
follow-up.  Even if our patient series was small and not ran-
domized or placebo-controlled, and control patients had a
higher risk of cancer recurrece than ERT/HRT patients, our
data on breast safety provides an important piece of infor-
mation to clinicians.Yet I would like to emphasize that to
prove the final safety of ERT/HRT in breast cancer patients,
much larger prospective and preferably placebo-controlled
trials are needed, and the follow-up time must be at least in
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Table 14.
Previous data on the use of estrogen replacement therapy following breast cancer
as compared with the the present data (NA=data not available)
Variable Wile Powles DiSaia Eden V-Sellin Natrajan U-Vrs˘c˘aj Present
1993 1993 1993 1995 1995 1999 1999 study
No. of patients 25 35 77 90 43 50 21 88
Stage of tumor, no. of patients (%) NA
Ca in situ 2 (7.7) 6 (7.8) 2 (4.7) 1 (2) 3 (3.4)
I 13 (52) 43 (55.8) 22 (51.2) 46 (92) 59 (67)
II 7 (28) 17 (22.1) 19 (44.2) 3 (6) 22 (25)
III 1 (4) 5 (6.5) 0 0 1 (1.1)
NA 2 (7.7) 6 (7.8) 0 0 3 (3.4)
Size of tumor, no. of patients (%)
T1 12 (34.3) 70 (79.5)
T2 14 (40) 17 (19.3)
T3 9 (25.7) 1 (1.1)
Axillary nodes, no. of patients (%)
Negative 12 (34.3) 58 (75.3) 72 (80) 28 (65.1) 46 (92) 14 (66.7) 72 (81.8)
Positive 10 (28.6) 13 (16.9) 18 (20) 8 (18.6) 3 (6) 7 (33.3) 10 (11.4)
NA 25 (100) 13 (37.1) 6 (7.8) 7 (16.3) 1 (2) 6 (6.8)
Estrogen reseptors,no. of patients (%)
Positive 28 (36.4) 12 (13.3) 7 (16.3) 12 (24) 5 (23.8) 57 (64.8)
Negative 12 (15.6) 10 (11.1) 20 (46.5) 7 (14) 16 (76.2) 15 (17)
NA 25 (100) 35 (100) 37 (48) 68 (75.6) 16 (37.2) 31 (62) 16 (18.2)
Duration of ERT use
(months) 35 15 27 18 31 66 28 29
(range) (6-78) (1-44) (1-233) (4-144) (24-142) (6-384) (3-72) (1-62)
No. of recurrences 3 2 7 6 1 3 4 7
Recurrence %/
woman-year 4 5 4 4 1 1 8 3
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Table 15.
Studies reporting on the incidences of tamoxifen–associated
endometrial pathologies
Author No of study Polyps Hyperplasia Carcinoma
Population % % %
Lahti et al. 1993 51 33.3 3.9 2.0
Kedar et al. 1994 61 8.2 16.4 0
Gibson et al. 1996 75 13.3 1.3 8.0
Cohen et al. 1997 175 8.0 15.4 0
Marconi et al. 1997 101 43.6 8.9 2.0
Ozsener et al. 1998 104 4.8 16.3 3.8
Seoud et al. 1999 67 10.4 4.5 1.5
Cohen et al. 1999 261 11.5 8.4 0.4
Barakat et al. 2000 111 4.5 2.7 0
Gerberet et al. 2000 247 5.7 3.2 1.2
the order of decades. In practice such studies are difficult to
arrange and perhaps even unethical. Amelioration of climac-
teric symptoms during ERT/HRT reveals the code of treat-
ment, and then it is no longer genuinely “placebo-control-
led”. Moreover, how can a physician offer a placebo to a
symptomatic climacteric patient wishing to receive estrogen.
We can hope that newer SERM´s will be useful and safe and
thus replace the use of ERT/HRT in breast cancer survivors.
Tamoxifen and toremifene showed both antiestrogenic and
estrogenic effects in our patients. They similarly worsened
vasomotor climacteric symptoms, but fortunately these symp-
toms were tolerable and/or alleviated by time during the
trial, and caused the discontinuation of antiestrogens only in
five patients (3%). Breast cancer patients have a 1.6-fold risk
of endometrial cancer compared to healthy women (Adami
et al 1997), and previous data imply that tamoxifen use still
increases this risk to 2-4-fold (Early Breast Cancer Trialists´
Collaborative Group 1998). No similar epidemiological evi-
dence exists for the carcinogenic effect of toremifene.
Tamoxifen has been shown to increase the endometrial thick-
ness and to cause the proliferation or hyperplasia of en-
dometrium, as well as endometrial polyps (Table 15) (Lahti
et al. 1993; Kedar et al. 1994; Gibson et al. 1996; Cohen et al.
1997; Marconi et al. 1997; Ozsener et al. 1998; Seoud et al.
1999; Cohen et al. 1999; Barakat et al. 2000; Gerberet et al.
2000). In our study tamoxifen and toremifene caused a sim-
ilar thickening in the endometrium but this did not correlate
with the histology of the endometrium. The incidence of
proliferative endometrium, which was before the start of reg-
imens 20.4% and 20.0% in tamoxifen and toremifene users,
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respectively, increased more markedly in women using
tamoxifen (47.8%) than in those using toremifene (32.2%).
Furthermore, the incidence of endometrial polyps was high-
er in patients using tamoxifen. These findings are in contra-
diction to the results of the previous prospective compari-
son between tamoxifen and toremifene showing the equal
number of endometrial polyps and proliferative endometrial
samples in the both groups (Tomas et al. 1995). One possi-
ble explanation to this contradiction might be the shorter
follow-up time and also the smaller number of study partic-
ipants in the study of Tomas et al.  In our study, yet only one
patient using toremifene developed endometrial carcinoma,
which was detected at 12 months´ follow-up visit. Thus
the incidence of endometrial cancer in antiestrogen users
(3/10 000 women-years) was lower than that in the Finnish
general population of the same age (6/10 000 women-years;
Finnish Cancer Registry 1997). Despite the limited number
of patients and short follow-up time, data in this study show
the safety of antiestrogens towards endometrium at least if
the duration of exposure does not exceed three years. Yet a
word of caution is needed because a 2-4-fold risk of en-
dometrial cancer in tamoxifen users has been seen in large
epidemiological studies (Fisher et al. 1994; Early Breast Can-
cer Trialists´ Collaborative Group 1998). Therefore a close
endometrial surveillance has been recommended for the long-
term users of antiestrogens (Barakat 1996).  The results of
this study suggest that such a surveillance is not needed
during the first 2-3 years of treatment. Based on animal stud-
ies, toremifene may be less estrogenic than tamoxifen  (Hir-
simäki et al. 1993). This may be reflected in women as well,
because toremifene had a weaker estrogenic effect in the
endometrium than did tamoxifen. At the present it could be
stated that large and long-term epidemiological data are need-
ed for the assessment of endometrial safety in the long-term
use of toremifene.
Tamoxifen has been shown to protect against myocardial
infarction (McDonald et al. 1995). The mechanism of this
action of antiestrogens is poorly understood, although ben-
eficial changes in blood lipids are likely (Love et al. 1994;
Grey et al. 1995; Gylling et al. 1995; Saarto et al. 1996). It is
also known that the vascular wall and endothelium are of
importance for vascular health (Ylikorkala et al. 1986; Mik-
kola et al. 1995), but no data existed on the effect of tamoxifen
or toremifene on these tissues.
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Therefore, an important finding of this study was that nei-
ther tamoxifen nor toremifene affected the production of
prostacyclin, TxA
2
, or NO. In contrast, toremifene, but not
tamoxifen, decreased the release of ET-1. The vascular func-
tion was also assessed directly by Doppler equipment.
Toremifene significantly reduced the pulsatility index (PI) in
the uterine artery, reflecting a vasodilatory effect of toremifene
in this artery, whereas this effect was not seen with tamoxifen.
In principle the vasodilatory effect of toremifene resembles
that of estrogens (Cacciatore et al. 1998). The toremifene-
induced vasodilatation at least in the uterine artery may have
been caused, in part, by the fall in ET-1. If a similar vasodil-
atation would appear to be systemic affecting the vascular
bed, toremifene may prove to have in that way cardiovascu-
lar protective properties; yet long-term detailed data on vas-
cular physiology during antiestrogen use are still needed.
Bone is also one target organ for the action of estrogen
and antiestrogens, and this is supported by the presence of
both a - and b -estrogen receptors in bone (Gustafsson 1999).
In our patients tamoxifen increased BMD, whereas toremifene
only prevented the menopause-induced bone loss. This find-
ing of the favorable effect of tamoxifen on bone is in line
with some previous data (Grey et al. 1995; Powles et al 1998;
Chang et al. 1996), but the bone-preserving effect of
toremifene is new. This study shows that by measuring uri-
nary NTx, it is possible to predict the subsequent change in
BMD. This data does not allow to deduce the reasons for the
difference in the bone effects of tamoxifen and toremifene
but, naturally, one can ask if the dosages used were really
equipotent and if equipotency is uniform. It can be possible
that estrogen receptors in bone cells are stimulated more by
tamoxifen than by toremifene. Furthermore, it can be possi-
ble that tamoxifen and toremifene have similar effect on bone
if used for longer periods, but the first year data of this study
do not allow further conclusion.
Summing up our comparative data I may conclude that
tamoxifen appears slightly more estrogenic than toremifene
on the endometrium and bone, whereas toremifene has
stronger estrogenic vasodilatory effect. Our results collected
during relatively short follow-up time do not allow us to
deduce if these differences persist during more prolonged
use of antiestrogens and if they lead to clinically significant
changes in patients´ outcomes.
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One hundred and thirty-one postmenopausal women with a
history of breast cancer were studied. Eighty-eight patients
started ERT/HRT and 43 patients served as controls; the ini-
tiation of ERT/HRT was not randomized and the study groups
were not strictly comparable. The patients were followed a
mean of 2.5 years. In 88 women starting ERT/HRT, five re-
currences and two contralateral breast cancers were detect-
ed. In the control group (n=43), four patients developed
recurrence and one a contralateral breast cancer. The risk
per year in ERT/HRT users was 7/216 woman-years (3%)
and in control group 5/111 woman-years (4%). Thus ERT/
HRT did not increase the risk of breast cancer recurrence
during this rather short period of time.
I also followed 167 women who started either tamoxifen
(20 mg/day, n=84) or toremifene (40 mg/day, n=83) as an
adjuvant therapy for st II-III breast cancer. The mean follow-
up time was 2.3 years. Tamoxifen and toremifene caused
similar vasomotor symptoms in postmenopausal breast can-
cer patients. During the follow-up, only one endometrial
cancer developed in a woman using toremifene. As a sign of
estrogenic effect, the rate of proliferative endometrium in-
creased from 20.4% to 47.8% in tamoxifen users, whereas
the rise from 20.0% to 32.2% in toremifene users was smaller
(p<0.0001). Also the number of endometrial polyps during
the antiestrogen use was greater in the tamoxifen group (17
polyps) than in the toremifene group (7 polyps) (p<0.05).
Prostacyclin and TxA
2
 may be mediators responsible for
the favorable cardiovascular effect of estrogen. Neither
tamoxifen nor toremifene caused any change in the produc-
tion of these vasoactive agents. Toremifene decreased the
level of vasoconstrictive ET-1 by 12.9% at 6 months (p=0.01),
and by 9.2% at 12 months (p=0.06), whereas tamoxifen did
not have any effect on ET-1.
Both tamoxifen and toremifene prevented postmenopau-
sal bone loss, as assessed by bone mineral density (BMD)
measurement. Tamoxifen increased BMD by 0.4-5%, where-
as toremifene did not increase it. Bone preserving effect could
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also be verified by measuring various bone markers reflect-
ing bone turn-over. Both tamoxifen and toremifene caused
a fall in urinary aminoterminal cross-linked telopeptide (NTx),
pyridinoline, and deoxypyridinoline, and tamoxifen caused
a fall in serum osteocalcin, aminoterminal and carboxyter-
minal propeptide of type I procollagen. Yet only NTx showed
correlations to the subsequent changes in BMD.
Based on the findings it is possible to make the following
conclusions:
1. Short lasting hormone replacement therapy in women
with a history of breast cancer is not related to a detri-
mental effect on the number of recurrences due to this
disease, but follow-up of this population was short and
the number of patients was small.
2. Tamoxifen and toremifene do not cause premalignant or
malignant endometrial lesions during the first 2-3 years
of their use. Thus close endometrial surveillance, as has
often been advocated recently, is not be warranted dur-
ing the first three years of antiestrogen treatment provid-
ing that patients are asymptomatic.
3. The probable cardiovascular protection provided by an-
tiestrogens is unlikely to be associated with any changes
in prostacyclin or TxA
2
. However, toremifene reduces
ET-1 and arterial resistance at least in the uterine artery.
4. Both tamoxifen and toremifene protects against bone loss
in postmenopausal breast cancer patients.
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